电话:
+86 (0512) 65829739
传真:
+86 (010) 6788 5057
电子邮件:
orders@antibodies-online.cn

RSV Pre-F0 protein (FITC,His tag)

This Recombinant RSV Pre-F0 protein is expressed in HEK-293 Cells.
产品编号 ABIN7488836
发货至: 中国
Contact our Customer Service for availability and price in your country. Contact Info

Our Local Distributor

中国
北京 101111
No. 88 KeChuang 6th Street
Beijing Economic Technological Development Area
Room 801-803
4A Biotech Co.,Ltd.
Tel +86 (0512) 65829739 传真 +86 (010) 6788 5057

Quick Overview for RSV Pre-F0 protein (FITC,His tag) (ABIN7488836)

抗原

RSV Pre-F0

蛋白类型

Recombinant

宿主

Human respiratory syncytial virus A

资源

  • 1
HEK-293 Cells

纯度

90 %
  • 标记

    FITC,His tag

    原理

    FITC-Labeled Human respiratory syncytial virus A (strain A2) Pre-F0 Protein, His Tag

    序列

    Gln 26- Leu 513

    产品特性

    FITC-Labeled Human respiratory syncytial virus A (strain A2) Pre-F0, His Tag is expressed from human 293 cells (HEK293). It contains AA Gln 26- Leu 513 (Accession # P03420).

    内毒素水平

    1.0 EU per μg
  • 想要此Protein的其他选项吗?

    !
    探索我们的预定义定制蛋白和定制蛋白服务!

    您的项目需要进一步定制吗?联系我们,了解我们的定制蛋白解决方案

  • 说明

    This protein carries a polyhistidine tag at the C-terminus. (FITC ,10xHis) The protein has a calculated MW of 56.1 kDa. The protein migrates as 60-65 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

    限制

    仅限研究用
  • 状态

    Lyophilized

    缓冲液

    PBS, pH 7.4

    储存条件

    -20 °C

    储存方法

    -20°C, avoid light
  • 抗原

    RSV Pre-F0

    背景

    Human respiratory syncytial virus (HRSV) is the most common etiological agent of acute lower respiratory tract disease in infants and can cause repeated infections throughout life. The RSV fusion glycoprotein (RSV F) is the principal target of RSV neutralizing antibodies in human sera. The RSV F is a type I viral fusion protein synthesized as inactive, single-chain polypeptides that assemble into trimers. RSV F fuses the viral and host cell membranes by irreversible protein refolding from the labile prefusion conformation to the stable post-fusion conformation. Both states exhibit epitopes targeted by neutralizing antibodies, and post-fusion RSV F is being developed as a vaccine candidate.

    分子量

    56.1 kDa
You are here: